LOXL2 is pivotal in stabilizing the ECM and facilitating the cross-linking of type I collagen molecules, which is essential for the formation of a structured scaffold that supports fibroblast growth and tissue integrity. The antibody did not change the SGRQ total score, DLCO, and FVC and failed to improve progression-free survival of IPF patients in a phase II trial (NCT01769196). It is also ineffective in alleviating bridging fibrosis of patients with NASH (NCT01672879). The gene discussed is LOXL2; the disease is metabolic dysfunction-associated steatohepatitis.